methoxy-morpholinyl-doxorubicin has been researched along with Leukemia P388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bargiotti, A; Farao, M; Grandi, M; Pastori, A; Pesenti, E; Pezzoni, G; Ripamonti, M; Spreafico, F; Suarato, A | 1 |
| Ballinari, D; Bargiotti, A; Capolongo, L; Faiardi, D; Grandi, M; Pezzoni, G; Spreafico, F; Suarato, A | 1 |
1 review(s) available for methoxy-morpholinyl-doxorubicin and Leukemia P388
| Article | Year |
|---|---|
Novel anthracycline analogs.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Leukemia P388; Mammary Neoplasms, Experimental; Mice | 1990 |
1 other study(ies) available for methoxy-morpholinyl-doxorubicin and Leukemia P388
| Article | Year |
|---|---|
In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
Topics: Animals; Doxorubicin; Female; Humans; Leukemia P388; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Neoplasms, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured | 1992 |